Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Technische Universitat Munchen

Charité – Universitätsmedizin Berlin

Universitaet Duisburg-essen

Charite - Universitaetsmedizin Berlin

Der Wissenschaft En E.v.

Bernhard Singer

Matthias Mann

Karl Lang

Markus Gerhard

Felix Meissner

Daniel Hornburg

Tobias Kruse

Vikas Duhan

Fan Steven Zhou

Anahita Javaheri

Han Remaut

Steffen Backert

Vishal Khairnar

The present invention relates to inhibitors of the interaction betweenIIopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based onHopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with

Methods for treatment ofinfections

An anti-CEACAM1 antibody includes at least one antibody heavy chain (V) domain having antigen binding sites CDR1, CDR2and CDR3, and at least one antibody light chain (V) domain having antigen binding sites CDR1, CDR2and CDR3. The antigen binding site CDR2has a sequence homology of at least 80% to the amino acid sequence WINTYTGEPT (SEQ ID No. 21).

Immunostimulatory anti-CEACAM1 antibody

The invention relates to new uses of soluble CEACAM6 or CEACAM8, or substances that are specific to soluble CEACAM8. Another object of the invention concerns the use of CEACAM1-specific and/or CEACAM6-specific compounds for apoptosis prevention in-vitro. The invention also relates to a method for screening compounds, which prevent apoptosis and a method for preventing apoptosis in human granulocytes.

Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis

The invention relates to the use of substances which are specific to CEACAM8 for the manufacture of a medicament for the prophylactic or therapeutic treatment of human autoimmune diseases and/or gout. Another object of the invention concerns the use of CEACAM8-specific substances for apoptosis induction in-vitro. The invention also relates to a method for screening substances which induce apoptosis and a method for inducing apoptosis in human granulocytes.

CEACAM8-related method for treating autoimmune diseases

Growing community of inventors

Essen, Germany

Bernhard Singer